Condition: CLDN18.2 Positive · Gastric/Gastroesophageal Junction Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.
This description comes directly from the study's public registry record.
Shuang Han · +86 512 6956 6088 · shuang.han@innoventbio.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07483554